YS Biopharma Co., Ltd. (LSB)

Overview

LakeShore Biopharma Co., Ltd is a prominent biopharmaceutical company that plays a vital role in the health sector by focusing on the discovery, development, manufacturing, and commercialization of vaccines and therapeutic biologics aimed at infectious diseases and cancer. Originating in 2002 and setting its foundations in Beijing, China, the company has expanded its operations to key global markets including the United States, Singapore, the United Arab Emirates, and the Philippines. Initially known as YS Biopharma Co., Ltd., it underwent a rebranding to LakeShore Biopharma Co., Ltd in May 2024, reflecting perhaps a strategic pivot or expansion in its business model. The company takes pride in its proprietary PIKA immunomodulating technology platform, which stands at the core of its innovative approach to vaccine and therapeutic biologic development.

Products and Services

• PIKA Rabies Vaccine

  The PIKA rabies vaccine represents a significant advancement in the fight against rabies, a fatal disease if left untreated. Utilizing the company's proprietary PIKA technology, this vaccine aims to offer improved immunogenicity and safety profiles compared to existing rabies vaccines, potentially revolutionizing preventive healthcare in rabies-endemic regions.

• PIKA Recombinant COVID-19 Vaccine

  In response to the global COVID-19 pandemic, LakeShore Biopharma has developed a recombinant vaccine using its PIKA technology. This innovative approach not only indicates the company's flexibility in addressing emergent global health crises but also its commitment to leveraging its core technologies to develop timely solutions that meet urgent public health needs.

• PIKA YS-ON-001

  PIKA YS-ON-001 showcases LakeShore Biopharma's expansion into therapeutic biologics for cancer treatment. Although specifics on its mechanism of action and targeted cancers are not provided, this development signifies the company's broader commitment to addressing a range of infectious diseases as well as complex conditions like cancer, utilizing its PIKA platform's full potential.